121 related articles for article (PubMed ID: 23266402)
1. Inhaled Dornase alfa (Pulmozyme) as a noninvasive treatment of atelectasis in mechanically ventilated patients.
Zitter JN; Maldjian P; Brimacombe M; Fennelly KP
J Crit Care; 2013 Apr; 28(2):218.e1-7. PubMed ID: 23266402
[TBL] [Abstract][Full Text] [Related]
2. Dornase alpha compared to hypertonic saline for lung atelectasis in critically ill patients.
Youness HA; Mathews K; Elya MK; Kinasewitz GT; Keddissi JI
J Aerosol Med Pulm Drug Deliv; 2012 Dec; 25(6):342-8. PubMed ID: 22413805
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children.
Riethmueller J; Borth-Bruhns T; Kumpf M; Vonthein R; Wiskirchen J; Stern M; Hofbeck M; Baden W
Pediatr Pulmonol; 2006 Jan; 41(1):61-6. PubMed ID: 16265663
[TBL] [Abstract][Full Text] [Related]
4. Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases.
Riethmueller J; Kumpf M; Borth-Bruhns T; Brehm W; Wiskirchen J; Sieverding L; Ankele C; Hofbeck M; Baden W
Cell Physiol Biochem; 2009; 23(1-3):205-10. PubMed ID: 19255515
[TBL] [Abstract][Full Text] [Related]
5. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
McCoy K; Hamilton S; Johnson C
Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
[TBL] [Abstract][Full Text] [Related]
6. Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients.
Pottecher J; Noll E; Borel M; Audibert G; Gette S; Meyer C; Gaertner E; Legros V; Carapito R; Uring-Lambert B; Sauleau E; Land WG; Bahram S; Meyer A; Geny B; Diemunsch P
Trials; 2020 Mar; 21(1):274. PubMed ID: 32183886
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological and clinical profiles of Dornase alfa (Pulmozyme®) in the management of cystic fibrosis patients to improve pulmonary function].
Kokubo H; Hosatani S; Ichikawa M
Nihon Yakurigaku Zasshi; 2013 Apr; 141(4):213-9. PubMed ID: 23575427
[No Abstract] [Full Text] [Related]
8. The use of dornase alpha for post-operative pulmonary atelectasis after congenital heart surgery.
Ozturk E; Tanidir IC; Haydin S; Onan IS; Odemis E; Bakir I
Cardiol Young; 2014 Oct; 24(5):807-12. PubMed ID: 23915544
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of atelectasis with Dornase alpha in a patient with congenital muscular dystrophy.
Crescimanno G; Marrone O
Rev Port Pneumol; 2014; 20(1):42-5. PubMed ID: 24095150
[TBL] [Abstract][Full Text] [Related]
10. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial.
Mainz JG; Schien C; Schiller I; Schädlich K; Koitschev A; Koitschev C; Riethmüller J; Graepler-Mainka U; Wiedemann B; Beck JF
J Cyst Fibros; 2014 Jul; 13(4):461-70. PubMed ID: 24594542
[TBL] [Abstract][Full Text] [Related]
11. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series.
Weber AG; Chau AS; Egeblad M; Barnes BJ; Janowitz T
Mol Med; 2020 Sep; 26(1):91. PubMed ID: 32993479
[TBL] [Abstract][Full Text] [Related]
12. Dornase alfa (Pulmozyme).
Wagener JS; Kupfer O
Curr Opin Pulm Med; 2012 Nov; 18(6):609-14. PubMed ID: 22990660
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Inhaled Dornase Alfa Administration in Non-Cystic Fibrosis Patients at a Tertiary Academic Medical Center.
Torbic H; Hacobian G
J Pharm Pract; 2016 Oct; 29(5):480-3. PubMed ID: 25667210
[TBL] [Abstract][Full Text] [Related]
14. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
15. Safety of recombinant human deoxyribonuclease as a rescue treatment for persistent atelectasis in newborns.
Fedakar A; Aydogdu C; Fedakar A; Ugurlucan M; Bolu S; Iskender M
Ann Saudi Med; 2012; 32(2):131-6. PubMed ID: 22366825
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of dornase alfa (Pulmozyme) therapy for acquired ventilator-associated infection in preterm infants.
Scala M; Hoy D; Bautista M; Palafoutas JJ; Abubakar K
Pediatr Pulmonol; 2017 Jun; 52(6):787-791. PubMed ID: 28052587
[TBL] [Abstract][Full Text] [Related]
17. Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19.
Holliday ZM; Earhart AP; Alnijoumi MM; Krvavac A; Allen LH; Schrum AG
Front Immunol; 2021; 12():714833. PubMed ID: 34745093
[TBL] [Abstract][Full Text] [Related]
18. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
[TBL] [Abstract][Full Text] [Related]
19. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
[TBL] [Abstract][Full Text] [Related]
20. Safety of endotracheal rh DNAse (Pulmozyme) for treatment of pulmonary atelectasis in mechanically ventilated children.
Boeuf B; Prouix F; Morneau S; Marton D; Lacroix J
Pediatr Pulmonol; 1998 Aug; 26(2):147. PubMed ID: 9727769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
